Yingchun Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yingchun Zhang has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Aihua Zhuang
Sun Yat-sen University Cancer Center 2 State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer Guangzhou, P. R. China
9 shared publications - Anqi Wang
Sun Yat-Sen University Cancer Center 1 Department of Musculoskeletal Oncology Guangzhou, P. R. China
9 shared publications - Chuangzhong Deng
Department of Musculoskeletal Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China
9 shared publications - Chuanquan Deng
Sun Yat-sen University Cancer Center 2 State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer Guangzhou, P. R. China
9 shared publications - Guohui Song
Sun Yat-Sen University Cancer Center 1 Department of Musculoskeletal Oncology Guangzhou, P. R. China
9 shared publications - Hao Wu
Sun Yat-Sen University Cancer Center 1 Department of Musculoskeletal Oncology Guangzhou, P. R. China
9 shared publications
Latest Publications
- Open Access
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Phase III Trial of Pegylated Liposomal Doxorubicin for Patients with Advanced and Refractory Desmoid Tumors
Table S3. Summary of toxicities reported by patients using PRO-CTCAE
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Phase III Trial of Pegylated Liposomal Doxorubicin for Patients with Advanced and Refractory Desmoid Tumors
Table S3. Summary of toxicities reported by patients using PRO-CTCAE
- Open Access
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Phase III Trial of Pegylated Liposomal Doxorubicin for Patients with Advanced and Refractory Desmoid Tumors
Figure S2. The examples of patients who achieved durable responses to PLD treatment
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Phase III Trial of Pegylated Liposomal Doxorubicin for Patients with Advanced and Refractory Desmoid Tumors
Figure S2. The examples of patients who achieved durable responses to PLD treatment
- Open Access
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Phase III Trial of Pegylated Liposomal Doxorubicin for Patients with Advanced and Refractory Desmoid Tumors
Figure S3. Distribution of PRO-CTCAE scores at successive time points during active therapy and maximum score post-baseline without and with baseline adjustment
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Phase III Trial of Pegylated Liposomal Doxorubicin for Patients with Advanced and Refractory Desmoid Tumors
Figure S3. Distribution of PRO-CTCAE scores at successive time points during active therapy and maximum score post-baseline without and with baseline adjustment
- Open Access
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Data from Phase III Trial of Pegylated Liposomal Doxorubicin for Patients with Advanced and Refractory Desmoid Tumors
Purpose:To evaluate the efficacy and safety of pegylated liposomal doxorubicin (PLD) in the treatment of desmoid tumors (DT).Patients and Methods:In this investigator-initiated, double-blind, phase III trial, we randomly assigned (in a 2:1 ratio) patients with advanced or refractory DTs to receive either PLD (50 mg/m2 intravenously) or placebo every 4 weeks for six cycles. Crossover from placebo to PLD was permitted upon disease progression. The primary endpoint was progression-free survival (PFS). The secondary endpoints were objective response and safety.Results:From November 2020 to March 2023, a total of 73 patients were assigned to receive PLD (49 patients) or placebo (24 patients). With a median follow-up of 16.1 months, PLD had a significantly longer PFS over placebo (not reached vs. 4.3 months), with an HR of 0.05 (95% confidence interval, 0.01–0.17; P < 0.001). The 2-year PFS rates were 90.4% with the PLD group and 19.6% with placebo. PFS benefit favored PLD across most prespecified subgroups. The confirmed objective response was observed in 19 (40.4%) patients in the PLD group and in one (4.3%) in the placebo group (P = 0.002). Common grade 3 or higher adverse events with PLD included neutrophil count decreased (10.6%), mucositis oral (6.4%), and white cell decreased (4.3%). Significant between-group differences in certain patient-reported toxicities were observed (P < 0.05).Conclusions:PLD significantly prolonged PFS and induced durable responses compared with placebo, with a favorable safety profile, for patients with progressive or symptomatic DTs.See related commentary by Dossa et al., p. 2127
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Phase III Trial of Pegylated Liposomal Doxorubicin for Patients with Advanced and Refractory Desmoid Tumors
Purpose:To evaluate the efficacy and safety of pegylated liposomal doxorubicin (PLD) in the treatment of desmoid tumors (DT).Patients and Methods:In this investigator-initiated, double-blind, phase III trial, we randomly assigned (in a 2:1 ratio) patients with advanced or refractory DTs to receive either PLD (50 mg/m2 intravenously) or placebo every 4 weeks for six cycles. Crossover from placebo to PLD was permitted upon disease progression. The primary endpoint was progression-free survival (PFS). The secondary endpoints were objective response and safety.Results:From November 2020 to March 2023, a total of 73 patients were assigned to receive PLD (49 patients) or placebo (24 patients). With a median follow-up of 16.1 months, PLD had a significantly longer PFS over placebo (not reached vs. 4.3 months), with an HR of 0.05 (95% confidence interval, 0.01–0.17; P < 0.001). The 2-year PFS rates were 90.4% with the PLD group and 19.6% with placebo. PFS benefit favored PLD across most prespecified subgroups. The confirmed objective response was observed in 19 (40.4%) patients in the PLD group and in one (4.3%) in the placebo group (P = 0.002). Common grade 3 or higher adverse events with PLD included neutrophil count decreased (10.6%), mucositis oral (6.4%), and white cell decreased (4.3%). Significant between-group differences in certain patient-reported toxicities were observed (P < 0.05).Conclusions:PLD significantly prolonged PFS and induced durable responses compared with placebo, with a favorable safety profile, for patients with progressive or symptomatic DTs.See related commentary by Dossa et al., p. 2127
- Open Access
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Phase III Trial of Pegylated Liposomal Doxorubicin for Patients with Advanced and Refractory Desmoid Tumors
Figure S1. Tumor volume change
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Phase III Trial of Pegylated Liposomal Doxorubicin for Patients with Advanced and Refractory Desmoid Tumors
Figure S1. Tumor volume change
- Open Access
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Phase III Trial of Pegylated Liposomal Doxorubicin for Patients with Advanced and Refractory Desmoid Tumors
Table S1. Representativeness of study participants
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Phase III Trial of Pegylated Liposomal Doxorubicin for Patients with Advanced and Refractory Desmoid Tumors
Table S1. Representativeness of study participants
- Open Access
- 8 January 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (11) , 2198-2205
Phase III Trial of Pegylated Liposomal Doxorubicin for Patients with Advanced and Refractory Desmoid Tumors
Purpose: To evaluate the efficacy and safety of pegylated liposomal doxorubicin (PLD) in the treatment of desmoid tumors (DT). Patients and Methods: In this investigator-initiated, double-blind, phase III trial, we randomly assigned (in a 2:1 ratio) patients with advanced or refractory DTs to receive either PLD (50 mg/m2 intravenously) or placebo every 4 weeks for six cycles. Crossover from placebo to PLD was permitted upon disease progression. The primary endpoint was progression-free survival (PFS). The secondary endpoints were objective response and safety. Results: From November 2020 to March 2023, a total of 73 patients were assigned to receive PLD (49 patients) or placebo (24 patients). With a median follow-up of 16.1 months, PLD had a significantly longer PFS over placebo (not reached vs. 4.3 months), with an HR of 0.05 (95% confidence interval, 0.01–0.17; P < 0.001). The 2-year PFS rates were 90.4% with the PLD group and 19.6% with placebo. PFS benefit favored PLD across most prespecified subgroups. The confirmed objective response was observed in 19 (40.4%) patients in the PLD group and in one (4.3%) in the placebo group (P = 0.002). Common grade 3 or higher adverse events with PLD included neutrophil count decreased (10.6%), mucositis oral (6.4%), and white cell decreased (4.3%). Significant between-group differences in certain patient-reported toxicities were observed (P < 0.05). Conclusions: PLD significantly prolonged PFS and induced durable responses compared with placebo, with a favorable safety profile, for patients with progressive or symptomatic DTs. See related commentary by Dossa et al., p. 2127
- 8 January 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (11) , 2198-2205
Open AccessPhase III Trial of Pegylated Liposomal Doxorubicin for Patients with Advanced and Refractory Desmoid Tumors
Purpose: To evaluate the efficacy and safety of pegylated liposomal doxorubicin (PLD) in the treatment of desmoid tumors (DT). Patients and Methods: In this investigator-initiated, double-blind, phase III trial, we randomly assigned (in a 2:1 ratio) patients with advanced or refractory DTs to receive either PLD (50 mg/m2 intravenously) or placebo every 4 weeks for six cycles. Crossover from placebo to PLD was permitted upon disease progression. The primary endpoint was progression-free survival (PFS). The secondary endpoints were objective response and safety. Results: From November 2020 to March 2023, a total of 73 patients were assigned to receive PLD (49 patients) or placebo (24 patients). With a median follow-up of 16.1 months, PLD had a significantly longer PFS over placebo (not reached vs. 4.3 months), with an HR of 0.05 (95% confidence interval, 0.01–0.17; P < 0.001). The 2-year PFS rates were 90.4% with the PLD group and 19.6% with placebo. PFS benefit favored PLD across most prespecified subgroups. The confirmed objective response was observed in 19 (40.4%) patients in the PLD group and in one (4.3%) in the placebo group (P = 0.002). Common grade 3 or higher adverse events with PLD included neutrophil count decreased (10.6%), mucositis oral (6.4%), and white cell decreased (4.3%). Significant between-group differences in certain patient-reported toxicities were observed (P < 0.05). Conclusions: PLD significantly prolonged PFS and induced durable responses compared with placebo, with a favorable safety profile, for patients with progressive or symptomatic DTs. See related commentary by Dossa et al., p. 2127